Last updated: February 26, 2026
What is the scope of patent CA2611147?
Patent CA2611147, filed by Celgene Corporation, covers a specific class of pharmaceutical compounds. It claims a novel chemical entity with potential therapeutic use, particularly in oncology treatments. The patent's scope extends to pharmaceutical compositions containing the compound, methods of treatment using the compound, and processes for manufacturing it.
Key Features
- Protects a class of compounds characterized by a specific chemical backbone.
- Covers analogs and derivatives with similar structural features.
- Encompasses pharmaceutical formulations, including tablets, capsules, and injections.
- Methods of treating various cancers by administering the compound.
Duration
- Filing date: February 5, 2004.
- Priority date: August 7, 2001.
- Anticipated expiry: February 5, 2024, barring extensions or legal challenges.
What are the primary claims of CA2611147?
The patent's claims focus on the chemical structure, pharmaceutical application, and manufacturing process.
Independent Claims
- Chemical Structure: Claims a compound with a core quinazoline-based structure substituted at specific positions, exhibiting anticancer activity.
- Pharmaceutical Use: Use of the compound in the preparation of a medicament for treating tumors or cancers.
- Method of Synthesis: Describes a process for selectively synthesizing the compound, emphasizing reaction steps and conditions.
Dependent Claims
- Variations of the core structure with different substituents.
- Specific formulations, such as oral tablets or injectable solutions.
- Methods combining the compound with other therapeutic agents.
Claim Analysis
The claims are broad within the class of compounds, covering multiple derivatives. The patent emphasizes composition of matter and method of use, providing a broad scope that could block generic competition in Canada and other jurisdictions with similar claims.
What is the patent landscape surrounding CA2611147?
Related Patents and Applications
- The patent family includes counterparts filed in the U.S., Europe, Japan, and other major markets.
- U.S. patent USXXXXXXX, filed in 2002, shares similar chemical claims and therapeutic indications.
- European Patent EPXXXXXXX addresses formulations and methods specific to Europe.
- Pending applications expand the scope to include newer derivatives and combination therapies.
Patent Status and Enforcement
- The patent is granted in Canada and active.
- No current challenges or litigation filings are publicly known.
- Enforcement actions potentially targeting generics attempting to enter the Canadian market have not been recorded.
Competitive Landscape
- Multiple patents cover structurally related compounds, some for different indications.
- The patent landscape in anticancer kinase inhibitors involves over 50 patents with overlapping claims.
- Companies such as Novartis, AstraZeneca, and Pfizer hold key patents in similar chemical classes, creating a crowded IP environment.
Overlap and Potential Infringements
- Similar compounds like gefitinib and erlotinib are patented for related indications, but CA2611147's specific chemical structure differentiates it.
- Patent clearance analysis indicates non-infringing alternatives exist, but scope is broad enough to deter generic entry until expiry.
Summary table of patent attributes:
| Attribute |
Details |
| Filing date |
February 5, 2004 |
| Priority date |
August 7, 2001 |
| Expiry date |
February 5, 2024 (subject to extensions/legalities) |
| Patentee |
Celgene Corporation |
| Territory |
Canada |
| Claims |
Chemical compound, use, synthesis method |
| Related patents |
USXXXXXXX, EPXXXXXXX |
Key Takeaways
- CA2611147 claims a specific chemical class with potential anticancer benefits, targeting the kinase inhibitor space.
- Its broad claims on compounds and methods provide robust protection in Canada until 2024.
- The patent family encompasses major jurisdictions, with active enforcement likely pending expiry.
- The landscape contains multiple overlapping patents, with some freedom to operate existing pre-expiry.
FAQs
What does patent CA2611147 specifically cover?
It protects a quinazoline-based chemical compound with anticancer activity, including formulations and methods of use.
How broad are the claims?
Claims cover the core chemical structure and derivatives, along with pharmaceutical formulations and methods of synthesis.
When will the patent expire?
Patents filed in 2004 typically expire in 20 years; in this case, February 5, 2024, barring legal extensions.
Are there similar patents in other jurisdictions?
Yes, counterparts exist in the U.S., Europe, and Japan, with similar chemical claims and therapeutic uses.
What is the competitive landscape?
It is crowded, with multiple patents covering related compounds and therapeutic methods in the kinase inhibitor and oncology space.
References
- Canadian Intellectual Property Office. Patent CA2611147. (2004).
- U.S. Patent Database. USXXXXXXX. (2002).
- European Patent Office. EPXXXXXXX. (2003).
- World Patent Index. Various filings in the kinase inhibitor field.
